BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person ImmuneBD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.

The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers, which provide powerful insight into how single cells respond to drugs or disease states. The panel will support a planned 1,000-patient immune profiling study, in partnership with the Penn Colton Center for Autoimmunity, expected to start this summer. The project will leverage the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, BD reagents, software and informatics, with BD teams managing reagents, instrumentation, and spectral data algorithms, and I3H teams serving as scientific and clinical leads. The team intends to publish a peer-reviewed manuscript describing the results of the study.

“This project demonstrates the power of collaboration between academia and industry,” said Dr. E. John Wherry, PhD, the Richard and Barbara Schiffrin President’s Distinguished Professor, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, and the director of the Colton Consortium for Autoimmunity. “We are bringing together cross-functional experts to transform human immune profiling for maximum impact, enabling deeper insights from our immune cells that could accelerate development of precise medical treatments.”

The collaboration reflects a shared vision of unlocking the power of the human immune system to advance science and health. It is made possible by the BD FACSDiscover™ A8 Cell Analyzer, which is the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, and the new BD Horizon™ Chroma solution for dried high-parameter panels. The project supports the commitment of both organizations to contribute to the research community through collaboration and knowledge sharing.

“High-parameter single-cell studies of this kind, once considered infeasible, are increasingly becoming central to better understanding the human immune system,” said Steve Conly, worldwide president of BD Biosciences. “Our ecosystem of industry-leading BD flow cytometers, single-cell systems, reagents, software and informatics, provide a critical missing puzzle piece that can support the important work of organizations like I3H to translate and deliver immunological insights into quantitative, actionable information for discovery and clinical care teams around the world.”

More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:

Investors:

Fallon McLoughlin

Adam Reiffe

Director, Public Relations

VP, Investor Relations

201.258.0361

201.847.6927

fallon.mcloughlin@bd.com

adam.reiffe@bd.com

Media for Penn Medicine:

Eric Horvath

Associate News Director

Penn Medicine

215-821-4289

Eric.horvath@pennmedicine.upenn.edu

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-penn-institute-for-immunology-and-immune-health-collaborate-to-advance-immunotherapy-through-flow-cytometry-302645260.html

SOURCE BD (Becton, Dickinson and Company)

Market Opportunity
FLOW Logo
FLOW Price(FLOW)
$0.1749
$0.1749$0.1749
-2.61%
USD
FLOW (FLOW) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

REX Shares’ Solana staking ETF sees $10M inflows, AUM tops $289M for first time

REX Shares’ Solana staking ETF sees $10M inflows, AUM tops $289M for first time

The post REX Shares’ Solana staking ETF sees $10M inflows, AUM tops $289M for first time appeared on BitcoinEthereumNews.com. Key Takeaways REX Shares’ Solana staking ETF saw $10 million in inflows in one day. Total inflows over the past three days amount to $23 million. REX Shares’ Solana staking ETF recorded $10 million in inflows yesterday, bringing total additions to $23 million over the past three days. The fund’s assets under management climbed above $289.0 million for the first time. The SSK ETF is the first U.S. exchange-traded fund focused on Solana staking. Source: https://cryptobriefing.com/rex-shares-solana-staking-etf-aum-289m/
Share
BitcoinEthereumNews2025/09/18 02:34
Microsoft Corp. $MSFT blue box area offers a buying opportunity

Microsoft Corp. $MSFT blue box area offers a buying opportunity

The post Microsoft Corp. $MSFT blue box area offers a buying opportunity appeared on BitcoinEthereumNews.com. In today’s article, we’ll examine the recent performance of Microsoft Corp. ($MSFT) through the lens of Elliott Wave Theory. We’ll review how the rally from the April 07, 2025 low unfolded as a 5-wave impulse followed by a 3-swing correction (ABC) and discuss our forecast for the next move. Let’s dive into the structure and expectations for this stock. Five wave impulse structure + ABC + WXY correction $MSFT 8H Elliott Wave chart 9.04.2025 In the 8-hour Elliott Wave count from Sep 04, 2025, we saw that $MSFT completed a 5-wave impulsive cycle at red III. As expected, this initial wave prompted a pullback. We anticipated this pullback to unfold in 3 swings and find buyers in the equal legs area between $497.02 and $471.06 This setup aligns with a typical Elliott Wave correction pattern (ABC), in which the market pauses briefly before resuming its primary trend. $MSFT 8H Elliott Wave chart 7.14.2025 The update, 10 days later, shows the stock finding support from the equal legs area as predicted allowing traders to get risk free. The stock is expected to bounce towards 525 – 532 before deciding if the bounce is a connector or the next leg higher. A break into new ATHs will confirm the latter and can see it trade higher towards 570 – 593 area. Until then, traders should get risk free and protect their capital in case of a WXY double correction. Conclusion In conclusion, our Elliott Wave analysis of Microsoft Corp. ($MSFT) suggested that it remains supported against April 07, 2025 lows and bounce from the blue box area. In the meantime, keep an eye out for any corrective pullbacks that may offer entry opportunities. By applying Elliott Wave Theory, traders can better anticipate the structure of upcoming moves and enhance risk management in volatile markets. Source: https://www.fxstreet.com/news/microsoft-corp-msft-blue-box-area-offers-a-buying-opportunity-202509171323
Share
BitcoinEthereumNews2025/09/18 03:50
The Digital WOW Explains How AI Is Affecting Digital Marketing

The Digital WOW Explains How AI Is Affecting Digital Marketing

WEST PALM BEACH, Fla., Dec. 19, 2025 /PRNewswire/ — The Digital WOW, powered by ConsultPR.net, announces new findings on how AI is affecting digital marketing.
Share
AI Journal2025/12/19 17:30